FRE (FRE) News
Follow FRE (FRE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Fresenius Plans to Cut Fresenius Medical Care Stake to About 20%
Fresenius plans to sell approximately 13.4 million Fresenius Medical Care shares, about 5% of its issued share capital, reducing its stake from 25% to about 20%.
EQUITY | Nov 11, 2026, 06:29 PM UTC
M
Fresenius Reports Higher Q3 Core Net Income and EBIT
Fresenius said revenue growth drove higher core net income and EBIT in the third quarter. It raised its fiscal 2026 outlook for core earnings per share and EBIT margin.
EQUITY | Nov 04, 2026, 06:32 AM UTC
M
Fresenius Lifts Outlook; WuXi Deal Expands Biosimilar Access
EARNINGS | Nov 04, 2026, 06:02 AM UTC
M
Fresenius Raises 2026 Outlook After Strong Third-Quarter Results
Fresenius lifted its full-year outlook after reporting higher-than-anticipated third-quarter results, with Kabi and Helios supporting earnings.
EARNINGS | Nov 04, 2026, 06:02 AM UTC
M
Fresenius Reports 5% Organic Revenue Growth in 3Q
EARNINGS | Nov 04, 2026, 05:55 AM UTC
L
Fresenius Reports Third-Quarter EBIT of EUR638 Million Before Special Items
EARNINGS | Nov 04, 2026, 05:46 AM UTC
M
Fresenius Narrows 2026 Adjusted EPS View
EARNINGS | Nov 04, 2026, 05:46 AM UTC
M
Fresenius Reports Third-Quarter Revenue of EUR 5.8B
EQUITY | Nov 04, 2026, 05:46 AM UTC
M
Fresenius Signs Exclusive Biosimilar Development Deal With WuXi
The agreement gives Fresenius exclusive options for up to 37 biosimilar candidates targeting original products with a combined market value exceeding 370 billion euros. Fresenius retains full economic rights and strategi
EQUITY | Nov 02, 2026, 01:03 PM UTC
M
Fresenius Signs Exclusive WuXi Biologics Biosimilars Deal
The agreement gives Fresenius access to up to 37 biosimilar candidates, with potential expansion to up to 66 molecules. Fresenius retains exclusive global commercialization rights; 2026 guidance is unchanged.
EQUITY | Nov 02, 2026, 06:48 AM UTC
M
Fresenius and WuXi Biologics Enter Biosimilar Development Agreement
The exclusive agreement gives Fresenius access to up to 37 identified biosimilar candidates over the next decade.
EQUITY | Nov 02, 2026, 06:47 AM UTC
L
Fresenius Backs 2026 Guidance
EARNINGS | Nov 02, 2026, 06:09 AM UTC
M
Fresenius acquires full ownership of mAbxience
Fresenius's acquisition of full ownership of mAbxience for up to 750 million euros is positive, as it gives the German healthcare group greater exposure to a growing market, Citi analysts write in a research note.
EQUITY | Oct 02, 2026, 09:46 AM UTC
M
Fresenius acquires remaining 45% stake in MAbxience for up to EUR 750 mln
Fresenius SE & Co. KGaA announced it has acquired the remaining 45% stake in MAbxience Holding S.L. for up to 750 million euros. The transaction was signed and completed on September 30.
EQUITY | Oct 01, 2026, 06:17 AM UTC
M
Fresenius Acquires Remaining 45% of mAbxience
Fresenius has acquired the remaining 45% of its biopharmaceutical joint venture, mAbxience.
EQUITY | Oct 01, 2026, 05:27 AM UTC
L
Fresenius Share Reaction to FDA Warning Letter Seems Overdone — Market Talk
Fresenius investors might have overreacted to news that the FDA sent a warning letter to the German healthcare group's Kabi pharmaceutical business alerting it to what the regulator called serious violations at a U.S. fa
REGULATION | Sep 30, 2026, 07:49 AM UTC
L
Fresenius Shares Drop on U.S. Regulator's Warning Letter to Pharma Business
By Joshua KirbyShares in Germany's Fresenius closed lower after the U.S. Food and Drug Administration said it alerted the company to what it called serious violations at a U.S. facility.In a letter dated Sept. 22, the FD
REGULATION | Sep 29, 2026, 04:22 PM UTC
L
Frendy Energy H1 Consolidated Net Profit €48,000
Frendy Energy SpA MIL:FRE:Further company coverage
NEWS | Sep 29, 2026, 11:25 AM UTC
L
Fresenius Expands European Production Capacity
FRESENIUS SE & CO. KGAA XETR:FRE
NEWS | Sep 25, 2026, 07:48 AM UTC
L
Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Firebrick Pharma Ltd ASX:FRE
NEWS | Sep 23, 2026, 01:28 AM UTC
M
DAX closes 0.12% lower as Porsche Automobil, BASF fall
The DAX Index fell 31 points, or 0.12%, on Thursday to close at 26,300, with Porsche Automobil, BASF and Mercedes-Benz AG among the biggest decliners.
EQUITY | Aug 13, 2026, 04:11 PM UTC
M
DAX opens 0.40% higher as Fresenius leads gainers
The DAX Index is up 105 points, or 0.40%, on Thursday, with Fresenius, Qiagen NV and Commerzbank among the top gainers while Brenntag, BASF and Hannover Rueck lag.
EQUITY | Aug 13, 2026, 07:31 AM UTC